Otsuka has launched Samsca (tolvaptan) for the treatment of hyponatraemia secondary to SIADH.

Tolvaptan is a selective vasopressin V2-receptor antagonist that binds to the receptor with a greater affinity than the arginine vasopressin found in the body. This causes an increase in urine excretion resulting in increased aquaresis, decreased urine osmolarity and increased serum sodium levels.

Care should be taken in patients with diabetes mellitus, urinary outflow obstruction and those at risk of demyelinisation syndromes. Fluid and electrolyte status should be closely monitored.

View Samsca drug record

Further information: Otsuka

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...